Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.86 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.55 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.50 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3218717 | 1.00 | BACE1 (0.86) | BACE1HDAC8NOX1PTGER1PTGER4 | |
| SCHEMBL3211707 | 0.93 | BACE1 (1.00) | BACE1HDAC8GSK3BAPPMAPT | |
| SCHEMBL3211720 | 0.93 | BACE1 (1.00) | BACE1HDAC8GSK3BAPPMAPT | |
| SCHEMBL3208390 | 0.88 | BACE1 (0.80) | BACE1APPMAPTALDH1A1 | |
| SCHEMBL3208402 | 0.88 | BACE1 (0.80) | BACE1APPMAPTALDH1A1 | |
| SCHEMBL3222986 | 0.88 | BACE1 (0.80) | BACE1HDAC8GSK3BAPPMAPT | |
| SCHEMBL3222998 | 0.88 | BACE1 (0.80) | BACE1HDAC8GSK3BAPPMAPT | |
| SCHEMBL15474827 | 0.85 | BACE1 (0.73) | BACE1HDAC8GSK3BAPPMAPT | |
| SCHEMBL15474828 | 0.85 | BACE1 (0.73) | BACE1HDAC8GSK3BAPPMAPT | |
| SCHEMBL16485292 | 0.85 | BACE1 (0.72) | BACE1HDAC8GSK3BAPPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962674-B2 | Curcumin derivative | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-02-24 | — | — | US | disclosed |
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2123637-A1 | NOVEL CURCUMIN DERIVATIVE | Tokyo Institute of Technology (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | BACE1, APP, BACE2 | BACE1 1/4885HDAC8 796/4885NOX1 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.